A recent Consumer Choice Center (CCC) report outlines the ongoing risks linked to compounded GLP-1 products and the actions policymakers should take to ensure patient safety.
The report adds to the growing industry concern that a shadow market born during the national shortage is exploiting federal loopholes to continue to sell illicit compounded versions of popular GLP-1 drugs used for weight loss, like semaglutide and tirzepatide.
This practice is confusing consumers and placing them at risk, the authors wrote.
“Patients fighting back against obesity and all its known comorbidities deserve safe, accountable and effective treatments, but knockoffs with unknown impurities are still flooding the market,” Fred Roeder, Managing Director at CCC and co-author of the report, said in a press release.
This echoes similar findings published earlier this year by the Center for Medicine in the Public Interest.
Read the full text here